A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Intramuscular Administration of a Single Dose of TNM002 in Healthy Subjects
Latest Information Update: 18 Sep 2023
At a glance
- Drugs TNM 002 (Primary)
- Indications Tetanus
- Focus Adverse reactions
- Sponsors Trinomab Biotech
- 02 Nov 2022 Status changed from recruiting to completed.
- 04 Feb 2021 According to a PerkinElmer media release, this trial was approved by the Australian Therapeutic Goods Administration (TGA) and Human Research Ethics Committee (HREC).
- 04 Feb 2021 According to a PerkinElmer media release, this trial is expected to be completed in August 2021.